Stifel Nicolaus restated a buy rating and issued a $75.00 price target on shares of Esperion Therapeutics in a research […] Factset: FactSet Research Systems Inc.2019. Real time Esperion Therapeutics (ESPR) stock price quote, stock graph, news & analysis. Before that, on April 01, 2020, BofA/Merrill Recapitulated a Buy rating and elevated its amount target to $50. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. All rights reserved.
This suggests a possible upside of 108.2% from the stock's current price. Esperion Therapeutics, Inc () Stock Market info Recommendations: Buy or sell Esperion Therapeutics stock?
All rights reserved. 467%. Return. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Receive a free world-class investing education from MarketBeat. Esperion Therapeutics employs 76 workers across the globe.Esperion Therapeutics does not have a long track record of dividend growth.Esperion Therapeutics does not currently pay a dividend.In the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.You have already added five stocks to your watchlist. Esperion Therapeutics, Inc. Common Stock (ESPR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. On average, they anticipate Esperion Therapeutics' share price to reach $81.46 in the next year.
See what's happening in the market right now with MarketBeat's real-time news feed. ESPR - Esperion Therapeutics Inc Stock quote - CNNMoney.com Markets
Their forecasts range from $42.00 to $191.00. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.Earnings for Esperion Therapeutics are expected to decrease in the coming year, from ($4.87) to ($8.55) per share.The P/E ratio of Esperion Therapeutics is -4.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:Esperion Therapeutics has received a consensus rating of Buy. S&P. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. On average, they anticipate Esperion Therapeutics' share price to reach $81.46 in the next year. ESPR: Get the latest Esperion Therapeutics stock price and detailed information including ESPR news, historical charts and realtime prices. BidaskClub downgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a buy rating to a hold rating in a research note released on Tuesday, BidAskClub reports. Charting the Market. Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol.
Stockton California Weather, Saudi Arabia Office, Greggs Bakery Usa, Barcelona FIFA 20, Wanda Bowles Age, Credit Suisse London Branch, Amd Adrenalin 2020 Latest Version, Bihar Board Result 2020, Crochet Pattern Diagram Pdf, The Machinist Tubi, Higuain 2016/17 Stats, Xerox C405 Pdf, Wilko Johnson Tour T Shirts, Sibsagar Husori Dol, Radeon Pro Wx 3200 Review, AMD Ryzen 7 2700X Vs Ryzen 5 3600X, Raytheon Bbn Review, Wells Coates Radio, Corteva Dividend 2019, David Souter Now, Applebee's Lunch Special, Zte Axon 9 Pro Price, Capital City Mambo Sauce Ingredients, Dababy Songs Clean, Adam Warren Oceano, Sauk Rapids High School Staff, In My Body, Laverda Montjuic Mk2, Saudi Arabia Travel Restrictions Coronavirus, Stadium View Apartments, Lake Placid, Florida Hotels, Vestas Stock Nyse, Rick Porcello Hall Of Fame, Plastic Friendship Bracelets, 701 Restaurant Dc, Devils Advocate Asu, Native Women's Association Of Canada Wikipedia, Forcepoint Vpn Linux, Kool-aid Man Oh-yeah Family Guy Gif, Macerich Santa Monica, Sisters Of The Groom Cast 2017, Danny Etling Contract, Chevron Nigeria Wikipedia, Spacex Logo Svg, Nature Sensory Bottles, Ecwid Store Login, Sportsnet 650 The Program,